Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
14.50B
Market cap14.50B
Price-Earnings ratio
18.25
Price-Earnings ratio18.25
Dividend yield
Dividend yield
Average volume
2.69M
Average volume2.69M
High today
$56.95
High today$56.95
Low today
$52.94
Low today$52.94
Open price
$56.31
Open price$56.31
Volume
4.20M
Volume4.20M
52 Week high
$57.57
52 Week high$57.57
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $54.05. The company's market cap stands at 14.5B, with a P/E ratio of 18.25.

On 2026-08-05, Exelixis(EXEL) stock traded between a low of $52.94 and a high of $56.95. Shares are currently priced at $54.05, which is +2.1% above the low and -5.1% below the high.

The Exelixis(EXEL)'s current trading volume is 4.2M, compared to an average daily volume of 2.69M.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $57.57 and a 52-week low of $33.76.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $57.57 and a 52-week low of $33.76.

EXEL News

Investing.com 5h
Earnings call transcript: Exelixis tops q2 2026 EPS view, shares fall after hours - Investing.com

...

Earnings call transcript: Exelixis tops q2 2026 EPS view, shares fall after hours - Investing.com
Simply Wall St 23h
Exelixis Stock Still Looks Cheap On Earnings While Returns Look Rich

Exelixis stock has already delivered a 225.4% total return over the past 5 years, yet on the current checks it still screens as attractively priced rather than...

Exelixis Stock Still Looks Cheap On Earnings While Returns Look Rich

Analyst ratings

52%

of 21 ratings
Buy
38.1%
Hold
52.4%
Sell
9.5%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.